Nog wat meer informatie over de studie:
Patienten die het goedkope niacine (vitamine B3) namen ipv het dure Zetia (cholesterolverlager) vertoonden een significante vermindering van de vaatwandverdikking (dichtslibbing) in de halsslagader.
The utter worthlessness of Big Pharma’s cholesterol drugs was demonstrated recently by a study published in the New England Journal of Medicine which showed that niacin (a low-cost B vitamin) out-performs Merck’s drug Zetia for preventing the build-up of arterial plaque, a symptom of cardiovascular disease.
As the study reveals, Zetia failed miserably.
Patients taking niacin showed a “significant shrinkage” in artery wall thickness,
while those on Zetia showed no such improvement.
At the same time, the rate of “cardiovascular events” in the niacin group was only one-fifth that in the Zetia group, demonstrating that niacin is far more effective at preventing heart attacks and other similar events than Zetia.
But curiously, as soon as niacin started to show a real benefit over Zetia, researchers cancelled the study.
The premature ending of the clinical trial stopped the process by which even more useful information about the benefits of niacin might have been learned.
Merck, the maker of Zetia, was likely horrified to learn that a low-cost B vitamin out-performed its blockbuster drug. Sales of its Zetia drug are reportedly over $5 billion (miljard). It’s no wonder: Zetia sells for as much as $3.89 per pill.
Niacin, on the other hand, costs as little as 6.7 cents per pill…
……
Verder lezen kan hier: